Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075278 | 0.81 | WDR5 (0.41) | RAB9ANPC1HPGDL3MBTL1 | |
| SCHEMBL13165329 | 0.81 | KDM4E (0.49) | SMN1; SMN2KDM4EAPPHRH3RAB9A | |
| SCHEMBL12519621 | 0.80 | TDP1 (0.44) | SMN1; SMN2APPMAOBRAB9ANPC1 | |
| SCHEMBL13165313 | 0.79 | KDM4E (0.38) | KDM4ERAB9AHPGDPOLB | |
| SCHEMBL13185146 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2HRH3MAOBRAB9ANPC1 | |
| SCHEMBL13165292 | 0.77 | TLR9 (0.47) | KDM4EMAPTMAPK1CA1CA2 | |
| SCHEMBL29053334 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EAPPHRH3MAOB | |
| SCHEMBL20216199 | 0.73 | HRH3 (0.43) | SMN1; SMN2KDM4EAPPHRH3MAOB | |
| SCHEMBL21108684 | 0.71 | CA1 (0.39) | HRH3MAPTMAPK1CA1CA2 | |
| SCHEMBL25557799 | 0.71 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EAPPHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9212181-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140213574-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8338439-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SMN1; SMN2 4194/4885KDM4E 866/4885APP 4790/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SMN1; SMN2 4194/4885KDM4E 866/4885APP 4790/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | SMN1; SMN2 2891/4885KDM4E 472/4885APP 4594/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SMN1; SMN2 4194/4885KDM4E 866/4885APP 4790/4885 |
| US-20140213574-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SMN1; SMN2 2352/4885KDM4E 3792/4885APP 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.